Skip to content

Menu

Network by SubjectChannelsBlogsHomeAboutContact
AI Legal Journal logo
Subscribe
Search
Close
PublishersBlogsNetwork by SubjectChannels
Subscribe

BioSlice Blog

Subscribe via RSS
Visit Blog
By: Arnold & Porter Kaye Scholer LLP

Blog Authors

Arnold & Porter
Eleri Abreo
Shama Aktar
Libby Amos-Stone
Christopher Bates
Eleanor Brittain
James Castro-Edwards
Mahnu Davar
Emma
Tom Fox
Ana Gonzalez-Lamuno
Sofia Holmquist
Heba Jalil
Zahrah Kazim
Jackie Mulryne
Ludovica Pizzetti
Anna Pothof
Alexander Roussanov
Dr Beatriz San Martin
Peter Schildkraut
Eftychia Sideri
Mimi Simmons
Camille Vermosen
Jami Vibbert
Joy Wee
Adela Williams
George Zografos

Latest from BioSlice Blog

BioSlice Blog

Virtual and Digital Health Digest – February 2026

By Alexander Roussanov, Fabien Roy, Dr Beatriz San Martin, Eleri Abreo, Ana Gonzalez-Lamuno, Sofia Holmquist & Heba Jalil
April 1, 2026

Welcome to the latest installment of Arnold & Porter’s Virtual and Digital Health Digest. This digest covers key virtual and digital health regulatory and public policy developments during February and early March 2026 from the the United Kingdom, and European Union.

February 2026 saw a period of substantial regulatory activity across both the UK and EU,…

BioSlice Blog

EDPB/EDPS Joint Opinion on the European Biotech Act Proposal: Key Data Protection Implications for Pharma and Life Sciences

By Alexander Roussanov, Camille Vermosen & Ana Gonzalez-Lamuno
March 19, 2026

On 16 December 2025, the European Commission published its Proposal for a Regulation establishing a framework of measures for strengthening the EU’s biotechnology and biomanufacturing sectors, particularly in the area of health (the “European Biotech Act” or the “Proposal”). The Proposal is ambitious in scope: it amends several major pieces of EU health legislation, including…

BioSlice Blog

Virtual and Digital Health Digest – January 2026

By Alexander Roussanov, Fabien Roy, Dr Beatriz San Martin, Eleri Abreo, Ana Gonzalez-Lamuno, Shama Aktar & Emma
March 2, 2026

Welcome to the latest installment of Arnold & Porter’s Virtual and Digital Health Digest. This digest covers key virtual and digital health regulatory and public policy developments during December 2025 and early January 2026 from the the United Kingdom, and European Union.

January 2026 saw significant activity as UK and EU authorities advanced major initiatives affecting…

BioSlice Blog

EU Digital Omnibus: What the Proposed Reforms Mean for Pharma and MedTech

By Alexander Roussanov, Fabien Roy & Camille Vermosen
February 26, 2026

On 19 November 2025, the European Commission published two legislative proposals – the Digital Omnibus on AI Regulation Proposal and the broader Digital Omnibus Regulation Proposal (“Proposals”) – as part of a wider initiative to simplify and streamline the EU’s digital regulatory framework. Together, the Proposals introduce targeted but significant amendments across a broad range…

BioSlice Blog

Virtual and Digital Health Digest – December 2025

By Alexander Roussanov, Eleri Abreo, Sofia Holmquist & Ana Gonzalez-Lamuno
January 30, 2026

Welcome to the latest installment of Arnold & Porter’s Virtual and Digital Health Digest. This digest covers key virtual and digital health regulatory and public policy developments during December 2025 and early January 2026 from the the United Kingdom, and European Union.…

BioSlice Blog

From complexity to clarity: How the EU Commission plans to overhaul the MDR and IVDR

By Alexander Roussanov, Eleri Abreo, Christopher Bates & Eftychia Sideri
December 17, 2025

Introduction

The European Commission has published its proposals on the amendment of the Medical Devices Regulation 2017/745 (MDR) and In Vitro Diagnostic Regulation 2017/746 (IVDR) (“the proposals”). This marks a pivotal moment for the EU healthcare and MedTech landscape, following a public consultation by the Commission in early 2025 (see our blog here) and…

BioSlice Blog

Updated NHS IP Guidance: Unlocking Healthcare Innovation

By Dr Beatriz San Martin
December 15, 2025

The UK government has published its first major update to the NHS Intellectual Property (IP) guidance in over two decades. Developed by the Department of Health and Social Care (DHSC) and NHS England with support from the National Institute for Health and Care Research (NIHR), the framework aims to remove long-standing barriers to innovation and…

BioSlice Blog

Virtual and Digital Health Digest – November 2025

By Alexander Roussanov, Eleri Abreo, Sofia Holmquist & Ana Gonzalez-Lamuno
December 8, 2025

Welcome to the latest installment of Arnold & Porter’s Virtual and Digital Health Digest. This digest covers key virtual and digital health regulatory and public policy developments during October and early November 2025 from the the United Kingdom, and European Union.…

BioSlice Blog

Digital Omnibus: The European Commission published its proposal to amend the GDPR, AI Act, Data Act and other related frameworks

By Alexander Roussanov, James Castro-Edwards & Eftychia Sideri
November 20, 2025

The EU Commission has published its proposal for the “Digital Omnibus” aimed to simplify and streamline the EU rules governing artificial intelligence, data protection, cybersecurity, and data use more broadly. The proposal seeks to amend several cornerstone EU regulations, including Regulation (EU) 2016/679 (GDPR), Regulation (EU) 2024/1689 (AI Act), Regulation (EU) 2023/2854 (Data Act), Directive…

BioSlice Blog

Rewriting the Rulebook: MHRA’s Vision for Rare Disease Therapies

By Adela Williams & Eleri Abreo
November 10, 2025

A new policy paper released on 2 November 2025 sets out the MHRA’s proposals on overhauling and transforming the UK regulation of rare therapies.

The intention is for a “bold new rulebook for rare therapies” to be published in 2026. Rare therapies is defined as medicinal products intended to treat rare diseases, specifically, conditions with a…

Post navigation

Older Posts 
LexBlog logo
Copyright © 2026, LexBlog. All Rights Reserved.
Legal content Portal by LexBlog LexBlog Logo